212 related articles for article (PubMed ID: 35021603)
41. Community analysis of large-scale molecular dynamics simulations elucidated dynamics-driven allostery in tyrosine kinase 2.
Lesgidou N; Vlassi M
Proteins; 2024 Apr; 92(4):474-498. PubMed ID: 37950407
[TBL] [Abstract][Full Text] [Related]
42. Urokinase stimulates human vascular smooth muscle cell migration via a phosphatidylinositol 3-kinase-Tyk2 interaction.
Kusch A; Tkachuk S; Haller H; Dietz R; Gulba DC; Lipp M; Dumler I
J Biol Chem; 2000 Dec; 275(50):39466-73. PubMed ID: 10995743
[TBL] [Abstract][Full Text] [Related]
43. Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors.
Cai Z; Wang J; Li Y; Shi Q; Jin L; Li S; Zhu M; Wang Q; Wong LL; Yang W; Lai H; Gong C; Yao Y; Liu Y; Zhang J; Yao H; Liu Q
Sci China Life Sci; 2023 Jan; 66(1):94-109. PubMed ID: 35982377
[TBL] [Abstract][Full Text] [Related]
44. [PI3K/AKT/mTOR Pathway and Pediatric T Acute Lymphoblastic Leukemia-Review].
Shi LX; Wang JH; Shi XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1269-74. PubMed ID: 27531814
[TBL] [Abstract][Full Text] [Related]
45. Constitutive STAT1 tyrosine phosphorylation in U937 monocytes overexpressing the TYK2 protein tyrosine kinase does not induce gene transcription.
Eilers A; Kanda K; Klose B; Krolewski J; Decker T
Cell Growth Differ; 1996 Jun; 7(6):833-40. PubMed ID: 8780896
[TBL] [Abstract][Full Text] [Related]
46. Targeting the mTOR Pathway in Leukemia.
Dinner S; Platanias LC
J Cell Biochem; 2016 Aug; 117(8):1745-52. PubMed ID: 27018341
[TBL] [Abstract][Full Text] [Related]
47. Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors.
Jensen LT; Attfield KE; Feldmann M; Fugger L
EBioMedicine; 2023 Nov; 97():104840. PubMed ID: 37863021
[TBL] [Abstract][Full Text] [Related]
48. Beating the Clock in T-cell Acute Lymphoblastic Leukemia.
Carroll WL; Aifantis I; Raetz E
Clin Cancer Res; 2017 Feb; 23(4):873-875. PubMed ID: 28007775
[TBL] [Abstract][Full Text] [Related]
49. Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression.
Shah K; Moharram SA; Kazi JU
Clin Epigenetics; 2018; 10():83. PubMed ID: 29951132
[TBL] [Abstract][Full Text] [Related]
50. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
[TBL] [Abstract][Full Text] [Related]
51. Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent.
Li Z; Gakovic M; Ragimbeau J; Eloranta ML; Rönnblom L; Michel F; Pellegrini S
J Immunol; 2013 Mar; 190(5):2335-44. PubMed ID: 23359498
[TBL] [Abstract][Full Text] [Related]
52. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Bartalucci N; Guglielmelli P; Vannucchi AM
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217
[TBL] [Abstract][Full Text] [Related]
53. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.
Schult C; Dahlhaus M; Glass A; Fischer K; Lange S; Freund M; Junghanss C
Anticancer Res; 2012 Feb; 32(2):463-74. PubMed ID: 22287733
[TBL] [Abstract][Full Text] [Related]
54. Investigation of the function of the PI3-Kinase / AKT signaling pathway for leukemogenesis and therapy of acute childhood lymphoblastic leukemia (ALL).
Ehm P; Grottke A; Bettin B; Jücker M
Cell Signal; 2022 May; 93():110301. PubMed ID: 35259456
[TBL] [Abstract][Full Text] [Related]
55. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
Araki K; Miyoshi Y
Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
[TBL] [Abstract][Full Text] [Related]
56. Functional characterization of the PI3K/AKT/MTOR signaling pathway for targeted therapy in B-precursor acute lymphoblastic leukemia.
Grüninger PK; Uhl F; Herzog H; Gentile G; Andrade-Martinez M; Schmidt T; Han K; Morgens DW; Bassik MC; Cleary ML; Gorka O; Zeiser R; Groß O; Duque-Afonso J
Cancer Gene Ther; 2022 Nov; 29(11):1751-1760. PubMed ID: 35794338
[TBL] [Abstract][Full Text] [Related]
57. MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
Canté-Barrett K; Spijkers-Hagelstein JA; Buijs-Gladdines JG; Uitdehaag JC; Smits WK; van der Zwet J; Buijsman RC; Zaman GJ; Pieters R; Meijerink JP
Leukemia; 2016 Sep; 30(9):1832-43. PubMed ID: 27174491
[TBL] [Abstract][Full Text] [Related]
58. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
59. TYK2 as a novel therapeutic target in psoriasis.
Elyoussfi S; Rane SS; Eyre S; Warren RB
Expert Rev Clin Pharmacol; 2023; 16(6):549-558. PubMed ID: 37287330
[TBL] [Abstract][Full Text] [Related]
60. Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells.
Bonelli M; Terenziani R; Zoppi S; Fumarola C; La Monica S; Cretella D; Alfieri R; Cavazzoni A; Digiacomo G; Galetti M; Petronini PG
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708306
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
